Selected research
Market Structure
Global NK1 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global NK1 Receptor Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of NK1 Receptor Antagonist include Glenmark, Heron Therapeutics, TerSera Therapeutics, Torrent Pharmaceuticals, Beijing Sihuan Pharmaceutical, Fresenius Kabi, Hansoh Pharma, Helsinn Healthcare and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global NK1 Receptor Antagonist market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of NK1 Receptor Antagonist and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents NK1 Receptor Antagonist revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the NK1 Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.
NK1 Receptor Antagonist Segment by Company
Glenmark
Heron Therapeutics
TerSera Therapeutics
Torrent Pharmaceuticals
Beijing Sihuan Pharmaceutical
Fresenius Kabi
Hansoh Pharma
Helsinn Healthcare
Jiangsu Hengrui Pharmaceuticals
Luoxin Pharmaceutical
Merck
Qilu Pharmaceutical
Yichang Humanwell Pharmaceutical
Chia Tai Tianqing Pharmaceutical
NK1 Receptor Antagonist Segment by Type
Netupitant
Maropitant
Rolapitant
Fosaprepitant
Aprepitant
Other
NK1 Receptor Antagonist Segment by Application
Hospital
Specialty Clinic
NK1 Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK1 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1 Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of NK1 Receptor Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK1 Receptor Antagonist industry.
Chapter 3: Detailed analysis of NK1 Receptor Antagonist companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK1 Receptor Antagonistrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Netupitant
- Maropitant
- Rolapitant
- Fosaprepitant
- Aprepitant
- Other
Applications
- Hospital
- Specialty Clinic
Companies covered
- Glenmark
- Heron Therapeutics
- TerSera Therapeutics
- Torrent Pharmaceuticals
- Beijing Sihuan Pharmaceutical
- Fresenius Kabi
- Hansoh Pharma
- Helsinn Healthcare
- Jiangsu Hengrui Pharmaceuticals
- Luoxin Pharmaceutical
- Merck
- Qilu Pharmaceutical
- Yichang Humanwell Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global NK1 Receptor Antagonist Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Netupitant
- 1.2.3 Maropitant
- 1.2.4 Rolapitant
- 1.2.5 Fosaprepitant
- 1.2.6 Aprepitant
- 1.2.7 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global NK1 Receptor Antagonist Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Specialty Clinic
- 1.4 Global Market Growth Prospects
- 1.5 Global NK1 Receptor Antagonist Growth Trends by Region
- 1.5.1 Global NK1 Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 NK1 Receptor Antagonist Market Size by Region (2021-2026)
- 1.5.3 NK1 Receptor Antagonist Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global NK1 Receptor Antagonist Market Dynamics
- 2.1 NK1 Receptor Antagonist Industry Trends
- 2.2 NK1 Receptor Antagonist Industry Drivers
- 2.3 NK1 Receptor Antagonist Industry Opportunities and Challenges
- 2.4 NK1 Receptor Antagonist Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global NK1 Receptor Antagonist Revenue by Company (2021-2026)
- 3.2 Global NK1 Receptor Antagonist Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global NK1 Receptor Antagonist Key Company Head office and Area Served
- 3.4 Global NK1 Receptor Antagonist Company, Product Type & Application
- 3.5 Global NK1 Receptor Antagonist Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global NK1 Receptor Antagonist Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 NK1 Receptor Antagonist Players Market Share by Revenue in 2025
- 3.6.3 2025 NK1 Receptor Antagonist Tier 1, Tier 2, and Tier 3
4 NK1 Receptor Antagonist Market by Type
- 4.1 Global NK1 Receptor Antagonist Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global NK1 Receptor Antagonist Market Size by Type (2021-2032)
- 4.3 Global NK1 Receptor Antagonist Market Size Share by Type (2021-2032)
5 NK1 Receptor Antagonist Market by Application
- 5.1 Global NK1 Receptor Antagonist Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global NK1 Receptor Antagonist Market Size by Application (2021-2032)
- 5.3 Global NK1 Receptor Antagonist Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Glenmark
- 6.1.1 Glenmark Company Information
- 6.1.2 Glenmark Business Overview
- 6.1.3 Glenmark NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Glenmark NK1 Receptor Antagonist Product Portfolio
- 6.1.5 Glenmark Recent Developments
- 6.2 Heron Therapeutics
- 6.2.1 Heron Therapeutics Company Information
- 6.2.2 Heron Therapeutics Business Overview
- 6.2.3 Heron Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Heron Therapeutics NK1 Receptor Antagonist Product Portfolio
- 6.2.5 Heron Therapeutics Recent Developments
- 6.3 TerSera Therapeutics
- 6.3.1 TerSera Therapeutics Company Information
- 6.3.2 TerSera Therapeutics Business Overview
- 6.3.3 TerSera Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio
- 6.3.5 TerSera Therapeutics Recent Developments
- 6.4 Torrent Pharmaceuticals
- 6.4.1 Torrent Pharmaceuticals Company Information
- 6.4.2 Torrent Pharmaceuticals Business Overview
- 6.4.3 Torrent Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
- 6.4.5 Torrent Pharmaceuticals Recent Developments
- 6.5 Beijing Sihuan Pharmaceutical
- 6.5.1 Beijing Sihuan Pharmaceutical Company Information
- 6.5.2 Beijing Sihuan Pharmaceutical Business Overview
- 6.5.3 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 6.5.5 Beijing Sihuan Pharmaceutical Recent Developments
- 6.6 Fresenius Kabi
- 6.6.1 Fresenius Kabi Company Information
- 6.6.2 Fresenius Kabi Business Overview
- 6.6.3 Fresenius Kabi NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Fresenius Kabi NK1 Receptor Antagonist Product Portfolio
- 6.6.5 Fresenius Kabi Recent Developments
- 6.7 Hansoh Pharma
- 6.7.1 Hansoh Pharma Company Information
- 6.7.2 Hansoh Pharma Business Overview
- 6.7.3 Hansoh Pharma NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Hansoh Pharma NK1 Receptor Antagonist Product Portfolio
- 6.7.5 Hansoh Pharma Recent Developments
- 6.8 Helsinn Healthcare
- 6.8.1 Helsinn Healthcare Company Information
- 6.8.2 Helsinn Healthcare Business Overview
- 6.8.3 Helsinn Healthcare NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio
- 6.8.5 Helsinn Healthcare Recent Developments
- 6.9 Jiangsu Hengrui Pharmaceuticals
- 6.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 6.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 6.9.3 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
- 6.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 6.10 Luoxin Pharmaceutical
- 6.10.1 Luoxin Pharmaceutical Company Information
- 6.10.2 Luoxin Pharmaceutical Business Overview
- 6.10.3 Luoxin Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 6.10.5 Luoxin Pharmaceutical Recent Developments
- 6.11 Merck
- 6.11.1 Merck Company Information
- 6.11.2 Merck Business Overview
- 6.11.3 Merck NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Merck NK1 Receptor Antagonist Product Portfolio
- 6.11.5 Merck Recent Developments
- 6.12 Qilu Pharmaceutical
- 6.12.1 Qilu Pharmaceutical Company Information
- 6.12.2 Qilu Pharmaceutical Business Overview
- 6.12.3 Qilu Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 6.12.5 Qilu Pharmaceutical Recent Developments
- 6.13 Yichang Humanwell Pharmaceutical
- 6.13.1 Yichang Humanwell Pharmaceutical Company Information
- 6.13.2 Yichang Humanwell Pharmaceutical Business Overview
- 6.13.3 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 6.13.5 Yichang Humanwell Pharmaceutical Recent Developments
- 6.14 Chia Tai Tianqing Pharmaceutical
- 6.14.1 Chia Tai Tianqing Pharmaceutical Company Information
- 6.14.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 6.14.3 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 6.14.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America
- 7.1 North America NK1 Receptor Antagonist Market Size (2021-2032)
- 7.2 North America NK1 Receptor Antagonist Market Size by Type
- 7.2.1 North America NK1 Receptor Antagonist Market Size by Type (2021-2026)
- 7.2.2 North America NK1 Receptor Antagonist Market Size by Type (2027-2032)
- 7.2.3 North America NK1 Receptor Antagonist Market Share by Type (2021-2032)
- 7.3 North America NK1 Receptor Antagonist Market Size by Application
- 7.3.1 North America NK1 Receptor Antagonist Market Size by Application (2021-2026)
- 7.3.2 North America NK1 Receptor Antagonist Market Size by Application (2027-2032)
- 7.3.3 North America NK1 Receptor Antagonist Market Share by Application (2021-2032)
- 7.4 North America NK1 Receptor Antagonist Market Size by Country
- 7.4.1 North America NK1 Receptor Antagonist Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 7.4.3 North America NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 7.4.4 North America NK1 Receptor Antagonist Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe NK1 Receptor Antagonist Market Size (2021-2032)
- 8.2 Europe NK1 Receptor Antagonist Market Size by Type
- 8.2.1 Europe NK1 Receptor Antagonist Market Size by Type (2021-2026)
- 8.2.2 Europe NK1 Receptor Antagonist Market Size by Type (2027-2032)
- 8.2.3 Europe NK1 Receptor Antagonist Market Share by Type (2021-2032)
- 8.3 Europe NK1 Receptor Antagonist Market Size by Application
- 8.3.1 Europe NK1 Receptor Antagonist Market Size by Application (2021-2026)
- 8.3.2 Europe NK1 Receptor Antagonist Market Size by Application (2027-2032)
- 8.3.3 Europe NK1 Receptor Antagonist Market Share by Application (2021-2032)
- 8.4 Europe NK1 Receptor Antagonist Market Size by Country
- 8.4.1 Europe NK1 Receptor Antagonist Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 8.4.3 Europe NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 8.4.4 Europe NK1 Receptor Antagonist Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China NK1 Receptor Antagonist Market Size (2021-2032)
- 9.2 China NK1 Receptor Antagonist Market Size by Type
- 9.2.1 China NK1 Receptor Antagonist Market Size by Type (2021-2026)
- 9.2.2 China NK1 Receptor Antagonist Market Size by Type (2027-2032)
- 9.2.3 China NK1 Receptor Antagonist Market Share by Type (2021-2032)
- 9.3 China NK1 Receptor Antagonist Market Size by Application
- 9.3.1 China NK1 Receptor Antagonist Market Size by Application (2021-2026)
- 9.3.2 China NK1 Receptor Antagonist Market Size by Application (2027-2032)
- 9.3.3 China NK1 Receptor Antagonist Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia NK1 Receptor Antagonist Market Size (2021-2032)
- 10.2 Asia NK1 Receptor Antagonist Market Size by Type
- 10.2.1 Asia NK1 Receptor Antagonist Market Size by Type (2021-2026)
- 10.2.2 Asia NK1 Receptor Antagonist Market Size by Type (2027-2032)
- 10.2.3 Asia NK1 Receptor Antagonist Market Share by Type (2021-2032)
- 10.3 Asia NK1 Receptor Antagonist Market Size by Application
- 10.3.1 Asia NK1 Receptor Antagonist Market Size by Application (2021-2026)
- 10.3.2 Asia NK1 Receptor Antagonist Market Size by Application (2027-2032)
- 10.3.3 Asia NK1 Receptor Antagonist Market Share by Application (2021-2032)
- 10.4 Asia NK1 Receptor Antagonist Market Size by Country
- 10.4.1 Asia NK1 Receptor Antagonist Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 10.4.3 Asia NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 10.4.4 Asia NK1 Receptor Antagonist Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa NK1 Receptor Antagonist Market Size (2021-2032)
- 11.2 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Type
- 11.2.1 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa NK1 Receptor Antagonist Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Application
- 11.3.1 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa NK1 Receptor Antagonist Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Country
- 11.4.1 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa NK1 Receptor Antagonist Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst